


Product Name : RD162
Cat. No. : PC-35346
CAS No. : 915087-27-3
Molecular Formula : C₂₂H₁₆F₄N₄O₂S
Molecular Weight : 476.45
Target : Androgen Receptor (AR)
Solubility : 10 mM in DMSO



Biological Activity

RD162 is a second-generation, orally available antiandrogen that binds to **androgen receptor** (AR) with IC₅₀ of 30.9 nM. RD162 suppresses growth and induces apoptosis in human prostate cancer cells in vitro. RD162 demonstrates greater relative affinity than the clinically used antiandrogen bicalutamide, reduces the efficiency of its nuclear translocation, and impairs both DNA binding to androgen response elements and recruitment of coactivators. RD162 induces tumor regression in mouse models of castration-resistant human prostate cancer.

References

- Tran C, et al. *Science*. 2009 May 8;324(5928):787-90.
Makkonen H, et al. *Mol Cell Endocrinol*. 2011 Jan 1;331(1):57-65.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com